An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis (Q33304297)

25 July 2017

1 reference

title

An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis (English)

1 reference

stem cell transplantation

25 July 2017

main subject

1 reference

1 reference

Vaishali Sanchorawala

object named as

Vaishali Sanchorawala

series ordinal

1

0 references

author name string

David C Seldin

series ordinal

2

1 reference

25 July 2017

publication date

1 December 2007

1 reference

25 July 2017

1 reference

25 July 2017

volume

14

1 reference

25 July 2017

issue

4

1 reference

25 July 2017

page(s)

261-269

1 reference

Amyloid fibril protein nomenclature -- 2002.

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

Autologous stem cell transplantation for primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

Diagnosis and management of the cardiac amyloidoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

Spontaneous rupture of the spleen in AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

Transplantation for amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

Outcome of autologous stem cell transplantation for AL amyloidosis in the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13506120701613984

10.1080/13506120701613984

21 January 2018

Identifiers

DOI

1 reference

25 July 2017

1 reference